298 related articles for article (PubMed ID: 28634358)
1. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.
Wang X; Cao M; Wu Y; Xu W; Wang Q; Ying T; Lu L; Jiang S
Molecules; 2021 Mar; 26(7):. PubMed ID: 33807292
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
4. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
5. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
6. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
Lu L; Pan C; Li Y; Lu H; He W; Jiang S
Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195
[TBL] [Abstract][Full Text] [Related]
7. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
8. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
9. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
10. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.
Eggink D; Bontjer I; Langedijk JP; Berkhout B; Sanders RW
J Virol; 2011 Oct; 85(20):10785-97. PubMed ID: 21835789
[TBL] [Abstract][Full Text] [Related]
11. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
12. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
13. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
15. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
16. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J; Wang Q; Xu W; Lu L; Jiang S
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
[TBL] [Abstract][Full Text] [Related]
17. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
18. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
19. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
Pan C; Lu H; Qi Z; Jiang S
AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
[TBL] [Abstract][Full Text] [Related]
20. Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.
Bastian AR; Contarino M; Bailey LD; Aneja R; Moreira DR; Freedman K; McFadden K; Duffy C; Emileh A; Leslie G; Jacobson JM; Hoxie JA; Chaiken I
Retrovirology; 2013 Dec; 10():153. PubMed ID: 24330857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
